Exonic expression variations of EGFR and KRAS in small bronchoscopic biopsies from patients with advanced non-small cell lung cancer treated by combined bevacizumab/erlotinib therapy followed by platinum-based chemotherapy at disease progression: A multicenter phase II trial SAKK19/05.
M. H. Brutsche
Honoraria - Roche
M. Frueh
No relevant relationships to disclose
S. Crowe
No relevant relationships to disclose
K. J. Na
No relevant relationships to disclose
C. Droege
No relevant relationships to disclose
D. C. Betticher
Consultant or Advisory Role - Roche
R. von Moos
Consultant or Advisory Role - Amgen; Novartis; Roche
Honoraria - Amgen; Roche
F. Zappa
Consultant or Advisory Role - Roche
M. Pless
Consultant or Advisory Role - Roche
L. Bubendorf
Consultant or Advisory Role - Roche
Honoraria - Roche
F. Baty
No relevant relationships to disclose